Protocol Ledger

NCT06510374 · Phase III · RECRUITING

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Interventional Phase III clinical trial protocol NCT06510374 sponsored by Ferring Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-01 Enrollment: 454 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06510374
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)454 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06510374
Protocol FieldVerified Registry Value
NCT IdentifierNCT06510374
Consolidated Lead SponsorFerring Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment454 participants (ESTIMATED)
Registered Start Date2024-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06510374
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI